http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 16 Oct 2026 17:58:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Olema+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/27198866.html si-local-file:///var/storage/secattach/20261016/27198866.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Olema+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/27198866.html Fri, 16 Oct 2026 17:58:00 -0400 OLMA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Olema+Pharmaceuticals%2C++++For%3A+Oct+12/27194054.html si-local-file:///var/storage/secattach/20261015/27194054.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Olema+Pharmaceuticals%2C++++For%3A+Oct+12/27194054.html Thu, 15 Oct 2026 17:00:00 -0400 OLMA http://www.streetinsider.com/Hot+List/Weakness+in+this+biotech+stock+is+a+buying+opportunity%3A+Stifel+/27069431.html <p>Stifel maintained its Buy rating on a clinical-stage biotechnology company, viewing the stock's recent selloff following a competitor's failed drug trial as a buying opportunity.</p><p>Olema Pharmaceuticals (NASDAQ: OLMA) shares fell nearly 10% in recent sessions after AstraZeneca (NYSE: AZN) announced Friday that its Phase 3 SERENA-4 trial "did not meet the primary endpoint of Progression-Free Survival (PFS); however, a numerical improvement was observed." </p><p>The failure marks the second oral SERD Phase 3 trial in 2026 to miss its primary endpoint in the first-line advanced ER+/HER2- breast cancer setting, following Roche's persevERA trial earlier this year.</p><p>Olema's own Phase 3 trial in http://www.streetinsider.com/Hot+List/Weakness+in+this+biotech+stock+is+a+buying+opportunity%3A+Stifel+/27069431.html Wed, 16 Sep 2026 13:00:00 -0400 AZN OLMA http://www.streetinsider.com/Hot+List/Weakness+in+this+biotech+stock+is+a+buying+opportunity%3A+Stifel+/27069431.html <p>Stifel maintained its Buy rating on a clinical-stage biotechnology company, viewing the stock's recent selloff following a competitor's failed drug trial as a buying opportunity.</p><p>Olema Pharmaceuticals (NASDAQ: OLMA) shares fell nearly 10% in recent sessions after AstraZeneca (NYSE: AZN) announced Friday that its Phase 3 SERENA-4 trial "did not meet the primary endpoint of Progression-Free Survival (PFS); however, a numerical improvement was observed." </p><p>The failure marks the second oral SERD Phase 3 trial in 2026 to miss its primary endpoint in the first-line advanced ER+/HER2- breast cancer setting, following Roche's persevERA trial earlier this year.</p><p>Olema's own Phase 3 trial in http://www.streetinsider.com/Hot+List/Weakness+in+this+biotech+stock+is+a+buying+opportunity%3A+Stifel+/27069431.html Wed, 16 Sep 2026 13:00:00 -0400 AZN OLMA http://www.streetinsider.com/Hot+List+Pro/Weakness+in+this+biotech+stock+is+a+buying+opportunity%3A+Stifel+/27069431.html <p>Stifel maintained its Buy rating on a clinical-stage biotechnology company, viewing the stock's recent selloff following a competitor's failed drug trial as a buying opportunity.</p><p>Olema Pharmaceuticals (NASDAQ: OLMA) shares fell nearly 10% in recent sessions after AstraZeneca (NYSE: AZN) announced Friday that its Phase 3 SERENA-4 trial "did not meet the primary endpoint of Progression-Free Survival (PFS); however, a numerical improvement was observed." </p><p>The failure marks the second oral SERD Phase 3 trial in 2026 to miss its primary endpoint in the first-line advanced ER+/HER2- breast cancer setting, following Roche's persevERA trial earlier this year.</p><p>Olema's own Phase 3 trial in http://www.streetinsider.com/Hot+List+Pro/Weakness+in+this+biotech+stock+is+a+buying+opportunity%3A+Stifel+/27069431.html Wed, 16 Sep 2026 13:00:00 -0400 AZN OLMA http://www.streetinsider.com/Hot+List+Pro/Weakness+in+this+biotech+stock+is+a+buying+opportunity%3A+Stifel+/27069431.html <p>Stifel maintained its Buy rating on a clinical-stage biotechnology company, viewing the stock's recent selloff following a competitor's failed drug trial as a buying opportunity.</p><p>Olema Pharmaceuticals (NASDAQ: OLMA) shares fell nearly 10% in recent sessions after AstraZeneca (NYSE: AZN) announced Friday that its Phase 3 SERENA-4 trial "did not meet the primary endpoint of Progression-Free Survival (PFS); however, a numerical improvement was observed." </p><p>The failure marks the second oral SERD Phase 3 trial in 2026 to miss its primary endpoint in the first-line advanced ER+/HER2- breast cancer setting, following Roche's persevERA trial earlier this year.</p><p>Olema's own Phase 3 trial in http://www.streetinsider.com/Hot+List+Pro/Weakness+in+this+biotech+stock+is+a+buying+opportunity%3A+Stifel+/27069431.html Wed, 16 Sep 2026 13:00:00 -0400 AZN OLMA http://www.streetinsider.com/Analyst+PT+Change/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2418+at+Goldman+Sachs/27055501.html Goldman Sachs analyst Richard Law lowered the price target on Olema Pharmaceuticals (NASDAQ: OLMA) to $18.00 (from $20.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2418+at+Goldman+Sachs/27055501.html Mon, 14 Sep 2026 07:53:29 -0400 OLMA http://www.streetinsider.com/Investing/Premarket+movers%3A+AI+stocks+slide+on+warnings%2C+Rumble%2C+Scholar+Rock+jump/27055460.html <p>Investing.com - U.S. stock index futures fell sharply on Monday, with technology stocks under pressure after several leading artificial intelligence executives called for a slower pace of AI development amid concerns over potential risks from the technology. </p> <p>By 05:52 ET (09:52 GMT), the Dow futures contract had fallen 150 points, or 0.3%, S&amp;P 500 futures had dropped 63 points, or 0.8%, and Nasdaq 100 futures had slumped 531 points, or 1.8%.</p> <p>Here are some of the biggest premarket U.S. stock movers today:</p> <p>Rumble shares surged as much as 28% in premarket trading after reports that Anthropic had agreed to a $13.7 billion computing contract http://www.streetinsider.com/Investing/Premarket+movers%3A+AI+stocks+slide+on+warnings%2C+Rumble%2C+Scholar+Rock+jump/27055460.html Mon, 14 Sep 2026 07:45:54 -0400 MARA OLMA SRRK http://www.streetinsider.com/Investing/Premarket+movers%3A+AI+stocks+slide+on+warnings%2C+Rumble%2C+Scholar+Rock+jump/27055460.html <p>Investing.com - U.S. stock index futures fell sharply on Monday, with technology stocks under pressure after several leading artificial intelligence executives called for a slower pace of AI development amid concerns over potential risks from the technology. </p> <p>By 05:52 ET (09:52 GMT), the Dow futures contract had fallen 150 points, or 0.3%, S&amp;P 500 futures had dropped 63 points, or 0.8%, and Nasdaq 100 futures had slumped 531 points, or 1.8%.</p> <p>Here are some of the biggest premarket U.S. stock movers today:</p> <p>Rumble shares surged as much as 28% in premarket trading after reports that Anthropic had agreed to a $13.7 billion computing contract http://www.streetinsider.com/Investing/Premarket+movers%3A+AI+stocks+slide+on+warnings%2C+Rumble%2C+Scholar+Rock+jump/27055460.html Mon, 14 Sep 2026 07:45:54 -0400 MARA OLMA SRRK http://www.streetinsider.com/Investing/Premarket+movers%3A+AI+stocks+slide+on+warnings%2C+Rumble%2C+Scholar+Rock+jump/27055460.html <p>Investing.com - U.S. stock index futures fell sharply on Monday, with technology stocks under pressure after several leading artificial intelligence executives called for a slower pace of AI development amid concerns over potential risks from the technology. </p> <p>By 05:52 ET (09:52 GMT), the Dow futures contract had fallen 150 points, or 0.3%, S&amp;P 500 futures had dropped 63 points, or 0.8%, and Nasdaq 100 futures had slumped 531 points, or 1.8%.</p> <p>Here are some of the biggest premarket U.S. stock movers today:</p> <p>Rumble shares surged as much as 28% in premarket trading after reports that Anthropic had agreed to a $13.7 billion computing contract http://www.streetinsider.com/Investing/Premarket+movers%3A+AI+stocks+slide+on+warnings%2C+Rumble%2C+Scholar+Rock+jump/27055460.html Mon, 14 Sep 2026 07:45:54 -0400 MARA OLMA SRRK http://www.streetinsider.com/General+News/Premarket+movers%3A+AI+stocks+slide+on+warnings%2C+Rumble%2C+Scholar+Rock+jump/27055460.html <p>Investing.com - U.S. stock index futures fell sharply on Monday, with technology stocks under pressure after several leading artificial intelligence executives called for a slower pace of AI development amid concerns over potential risks from the technology. </p> <p>By 05:52 ET (09:52 GMT), the Dow futures contract had fallen 150 points, or 0.3%, S&amp;P 500 futures had dropped 63 points, or 0.8%, and Nasdaq 100 futures had slumped 531 points, or 1.8%.</p> <p>Here are some of the biggest premarket U.S. stock movers today:</p> <p>Rumble shares surged as much as 28% in premarket trading after reports that Anthropic had agreed to a $13.7 billion computing contract http://www.streetinsider.com/General+News/Premarket+movers%3A+AI+stocks+slide+on+warnings%2C+Rumble%2C+Scholar+Rock+jump/27055460.html Mon, 14 Sep 2026 07:45:54 -0400 MARA OLMA SRRK http://www.streetinsider.com/General+News/Premarket+movers%3A+AI+stocks+slide+on+warnings%2C+Rumble%2C+Scholar+Rock+jump/27055460.html <p>Investing.com - U.S. stock index futures fell sharply on Monday, with technology stocks under pressure after several leading artificial intelligence executives called for a slower pace of AI development amid concerns over potential risks from the technology. </p> <p>By 05:52 ET (09:52 GMT), the Dow futures contract had fallen 150 points, or 0.3%, S&amp;P 500 futures had dropped 63 points, or 0.8%, and Nasdaq 100 futures had slumped 531 points, or 1.8%.</p> <p>Here are some of the biggest premarket U.S. stock movers today:</p> <p>Rumble shares surged as much as 28% in premarket trading after reports that Anthropic had agreed to a $13.7 billion computing contract http://www.streetinsider.com/General+News/Premarket+movers%3A+AI+stocks+slide+on+warnings%2C+Rumble%2C+Scholar+Rock+jump/27055460.html Mon, 14 Sep 2026 07:45:54 -0400 MARA OLMA SRRK http://www.streetinsider.com/General+News/Premarket+movers%3A+AI+stocks+slide+on+warnings%2C+Rumble%2C+Scholar+Rock+jump/27055460.html <p>Investing.com - U.S. stock index futures fell sharply on Monday, with technology stocks under pressure after several leading artificial intelligence executives called for a slower pace of AI development amid concerns over potential risks from the technology. </p> <p>By 05:52 ET (09:52 GMT), the Dow futures contract had fallen 150 points, or 0.3%, S&amp;P 500 futures had dropped 63 points, or 0.8%, and Nasdaq 100 futures had slumped 531 points, or 1.8%.</p> <p>Here are some of the biggest premarket U.S. stock movers today:</p> <p>Rumble shares surged as much as 28% in premarket trading after reports that Anthropic had agreed to a $13.7 billion computing contract http://www.streetinsider.com/General+News/Premarket+movers%3A+AI+stocks+slide+on+warnings%2C+Rumble%2C+Scholar+Rock+jump/27055460.html Mon, 14 Sep 2026 07:45:54 -0400 MARA OLMA SRRK http://www.streetinsider.com/Analyst+PT+Change/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2430+at+Stifel/27054710.html <p>Stifel analyst Laura Prendergast lowered the price target on Olema Pharmaceuticals (NASDAQ: OLMA) to $30.00 (from $48.00) while maintaining a Buy rating.</p><p>The analyst comments "On Friday AZN announced that their Ph3 SERENA-4 trial 'did not meet the primary endpoint of PFS, however a numerical improvement was observed.' This marks the second oral SERD Ph3 trial in 2026 to fail in the 1L advanced ER+/HER2- breast cancer (aBC) setting; Roche's persevERA trial failed earlier this year despite showing an ~5mo PFS delta. OLMA's Ph3 in this setting, OPERA-02, has been enrolling very well and is expected to have topline data in http://www.streetinsider.com/Analyst+PT+Change/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2430+at+Stifel/27054710.html Mon, 14 Sep 2026 05:56:23 -0400 OLMA http://www.streetinsider.com/Analyst+Comments/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2430+at+Stifel/27054710.html <p>Stifel analyst Laura Prendergast lowered the price target on Olema Pharmaceuticals (NASDAQ: OLMA) to $30.00 (from $48.00) while maintaining a Buy rating.</p><p>The analyst comments "On Friday AZN announced that their Ph3 SERENA-4 trial 'did not meet the primary endpoint of PFS, however a numerical improvement was observed.' This marks the second oral SERD Ph3 trial in 2026 to fail in the 1L advanced ER+/HER2- breast cancer (aBC) setting; Roche's persevERA trial failed earlier this year despite showing an ~5mo PFS delta. OLMA's Ph3 in this setting, OPERA-02, has been enrolling very well and is expected to have topline data in http://www.streetinsider.com/Analyst+Comments/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2430+at+Stifel/27054710.html Mon, 14 Sep 2026 05:56:23 -0400 OLMA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Olema+Pharmaceuticals%2C++++For%3A+Aug+11++Filed+by%3A+O%26apos%3BByrne+Jason/26921987.html si-local-file:///var/storage/secattach/20260813/26921987.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Olema+Pharmaceuticals%2C++++For%3A+Aug+11++Filed+by%3A+O%26apos%3BByrne+Jason/26921987.html Thu, 13 Aug 2026 16:34:00 -0400 O.49219591 OLMA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Olema+Pharmaceuticals%2C++++For%3A+Aug+11++Filed+by%3A+O%26apos%3BByrne+Jason/26921987.html si-local-file:///var/storage/secattach/20260813/26921987.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Olema+Pharmaceuticals%2C++++For%3A+Aug+11++Filed+by%3A+O%26apos%3BByrne+Jason/26921987.html Thu, 13 Aug 2026 16:34:00 -0400 O.49219591 OLMA http://www.streetinsider.com/Analyst+PT+Change/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2446+at+JPMorgan/26917555.html JPMorgan analyst Anupam Rama lowered the price target on Olema Pharmaceuticals (NASDAQ: OLMA) to $46.00 (from $52.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2446+at+JPMorgan/26917555.html Thu, 13 Aug 2026 09:08:50 -0400 OLMA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Olema+Pharmaceuticals%2C++++For%3A+Aug+13/26916300.html si-local-file:///var/storage/secattach/20260813/26916300.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Olema+Pharmaceuticals%2C++++For%3A+Aug+13/26916300.html Thu, 13 Aug 2026 07:05:00 -0400 O.49219591 OLMA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Olema+Pharmaceuticals%2C++++For%3A+Aug+13/26916300.html si-local-file:///var/storage/secattach/20260813/26916300.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Olema+Pharmaceuticals%2C++++For%3A+Aug+13/26916300.html Thu, 13 Aug 2026 07:05:00 -0400 O.49219591 OLMA http://www.streetinsider.com/Analyst+PT+Change/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2436+at+H.C.+Wainwright/26900956.html (Updated - August 11, 2026 6:53 AM EDT) <p>H.C. Wainwright analyst Emily Bodnar lowered the price target on Olema Pharmaceuticals (NASDAQ: OLMA) to $36.00 (from $38.00) while maintaining a Buy rating.</p><p>The analyst commented: "Yesterday after market close, Olema reported 2Q26 earnings and provided a corporate update. The company announced that it had completed enrollment in the pivotal Phase 3 OPERA-01 trial evaluating palazestrant (pala) monotherapy vs SOC endocrine therapy (ET) in 2L/3L ER+/HER2- mBC, with topline data now expected in 1Q27 vs prior guidance of Fall 2026. We remind that OPERA-01 (n=510) was designed in two parts, with Part 1 randomizing http://www.streetinsider.com/Analyst+PT+Change/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2436+at+H.C.+Wainwright/26900956.html Tue, 11 Aug 2026 06:53:54 -0400 OLMA http://www.streetinsider.com/Analyst+Comments/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2436+at+H.C.+Wainwright/26900956.html (Updated - August 11, 2026 6:53 AM EDT) <p>H.C. Wainwright analyst Emily Bodnar lowered the price target on Olema Pharmaceuticals (NASDAQ: OLMA) to $36.00 (from $38.00) while maintaining a Buy rating.</p><p>The analyst commented: "Yesterday after market close, Olema reported 2Q26 earnings and provided a corporate update. The company announced that it had completed enrollment in the pivotal Phase 3 OPERA-01 trial evaluating palazestrant (pala) monotherapy vs SOC endocrine therapy (ET) in 2L/3L ER+/HER2- mBC, with topline data now expected in 1Q27 vs prior guidance of Fall 2026. We remind that OPERA-01 (n=510) was designed in two parts, with Part 1 randomizing http://www.streetinsider.com/Analyst+Comments/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2436+at+H.C.+Wainwright/26900956.html Tue, 11 Aug 2026 06:53:54 -0400 OLMA http://www.streetinsider.com/Analyst+PT+Change/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2459+at+Citi/26900105.html Citi analyst Yigal Nochomovitz lowered the price target on Olema Pharmaceuticals (NASDAQ: OLMA) to $59.00 (from $62.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Olema+Pharmaceuticals+%28OLMA%29+PT+Lowered+to+%2459+at+Citi/26900105.html Tue, 11 Aug 2026 04:46:58 -0400 OLMA http://www.streetinsider.com/Earnings/Olema+Pharmaceuticals%2C+Inc.+%28OLMA%29+Misses+Q2+EPS+by+6c/26898388.html <p>Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) reported Q2 EPS of ($0.61), $0.06 worse than the analyst estimate of ($0.55).</p><p>For earnings history and earnings-related data on Olema Pharmaceuticals, Inc. (OLMA) <a href="http://www.streetinsider.com/ec_earnings.php?q=OLMA">click here</a>.</p> http://www.streetinsider.com/Earnings/Olema+Pharmaceuticals%2C+Inc.+%28OLMA%29+Misses+Q2+EPS+by+6c/26898388.html Mon, 10 Aug 2026 16:28:11 -0400 OLMA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Olema+Pharmaceuticals%2C++++For%3A+Jun+30/26897976.html si-local-file:///var/storage/secattach/20260810/26897976.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Olema+Pharmaceuticals%2C++++For%3A+Jun+30/26897976.html Mon, 10 Aug 2026 16:11:00 -0400 O.49219591 OLMA